HOME >> MEDICINE >> NEWS
FDA approves EPZICOM

Research Triangle Park, NC August 2, 2004 - EPZICOMTM, a new product combining two HIV medicines into one tablet dosed once a day (QD) with no food or fluid requirements, was cleared for prescription use today by the U.S. Food and Drug Administration (FDA). EPZICOM combines two widely-used nucleoside reverse transcriptase inhibitors (NRTIs), EPIVIR(R) (lamivudine, 3TC) and ZIAGEN(R) (abacavir sulfate, ABC) for use in combination with other antiretroviral drugs. The brand name, EPZICOM, is an acronym for EPIVIR and ZIAGEN in COMbination. EPZICOM Tablets are recommended for use in combination with antiretroviral drugs from different pharmacological classes and not with other nucleoside/nucleotide reverse transcriptase inhibitors.

GlaxoSmithKline (GSK), manufacturer of EPZICOM, announced today that it is initiating a voucher program for EPZICOM that will provide a 60 day supply of EPZICOM directly to patients at no cost. These vouchers will be available in limited supply through participating healthcare providers for a limited time. Vouchers can be used to initiate antiretroviral therapy for therapy-nave patients or for therapy-experienced patients who require a change in regimen.

"EPZICOM marks an important advance in GSK's ongoing commitment to provide new options in antiretroviral therapy for HIV patients," said Doug Manion, vice president for HIV Clinical Research for the Infectious Diseases Medicines Development Center (MDC) for GSK. "The voucher program will be particularly beneficial to people who are not covered by private health care plans or in specific states where the drug is not yet available on all formularies."

Dr. Manion added that EPZICOM provides patients and treaters with a flexible and potent dosing option that combines two NRTIs that have been widely used in antiretroviral therapy for years. "Prescribers are familiar with these medications, which have an established resistance and long-term safety p
'"/>

Contact: Annie Noland
anoland@pcipr.com
Public Communications Inc.
2-Aug-2004


Page: 1 2 3 4 5

Related medicine news :

1. FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain
2. FDA approves Enablex for treatment of overactive bladder
3. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
4. FDA approves Adderall XR (R) to treat ADHD in adults
5. FDA approves new labelling for Seroquel in bioplar mania
6. FDA approves Enbrel to treat psoriasis
7. FDA approves Climara Pro to treat menopause symptoms
8. FDA approves new approach to schizophrenia treatment
9. FDA approves new HIV protease inhibitor, Lexiva (TM)
10. FDA approves Wellbutrin XL(TM)
11. FDA approves Baxters ADVATE for the treatment of hemophilia A

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA approves EPZICOM

(Date:3/1/2015)... (PRWEB) March 01, 2015 Women’s Excellence ... treat Overactive Bladder (OAB) symptoms, such as a strong need ... another type of medication (anticholinergic) does not work well enough ... option that takes another approach to targeting the source of ... on the nerves and bladder muscle, blocking the signals that ...
(Date:3/1/2015)... Ticket Down is a reputable source for ... Soldier Field. Deadheads have been anxiously anticipating this blockbuster ... Dead was formed 50 years ago back in the 60s ... until the untimely death of Jerry Garcia in 1995. ... blues, reggae, rock, bluegrass, folk, space rock and country to ...
(Date:3/1/2015)... Aliso Viejo, California (PRWEB) March 01, 2015 ... have announced a new transition pack for ... users to add accordion style transitions to any FCPX ... Studios. “We’ve given our users the tools needed to ... FCPX media.” , The user gets many different controls ...
(Date:2/28/2015)... 2015 In a recent episode of ... Game Change Athlete Development Services and Consultancy ... benefits of athlete development and player engagement during and ... challenges that athletes face and how off-field activities are ... Fletcher became involved in athlete development issues while in ...
(Date:2/28/2015)... Morristown, NJ (PRWEB) February 28, 2015 ... Month—is a good time to remind ourselves and ... be ignored, say Atlantic NeuroSurgical Specialists (ANS). , ... (TBI), which account for 75% of TBIs. There ... word concussion may sound benign, but it is ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3
(Date:2/27/2015)... Feb. 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" ... today announced financial results for its first quarter ended ... months ended December 31, 2014, revenue was $1,336,685. Operating ... $229,820 or $0.02 per share.  Covalon,s ... am very pleased with the significant progress we have ...
(Date:2/27/2015)... Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: UPI ... markets innovative proprietary products to treat voiding dysfunctions, today ... ROTH Conference on Tuesday, March 10, 2015. Rob ... , Chief Financial Officer, will present at 4:00 p.m. ... at the conference at the Ritz Carlton in ...
(Date:2/26/2015)... SANTA CLARA, Calif. , Feb. 27, 2015  Finesse ... Finesse Solutions announced the expansion of ... The opening is planned for mid-March and access for ... access from the A-563, and located adjacent to the ... occupied by the Finesse automation engineering team and allow Finesse ...
Breaking Medicine Technology:Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Uroplasty to Participate in the 27th Annual ROTH Conference 2New Finesse Office in United Kingdom 2
Cached News: